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Abstract
Background: We piloted a randomised controlled trial (RCT) comparing pregnancy outcomes among women with
booking gestational diabetes (GDM) receiving immediate or deferred treatment.
Methods: Consecutive, consenting women < 20 weeks gestation, with GDM risk factors attending the hospital
book-in clinic, completed an oral glucose tolerance test (OGTT). Clinicians were blinded to OGTT results. Women
fulfilling World Health Organisation GDM criteria were randomised to either clinic referral /ongoing treatment
(Treated Group n = 11), or no treatment (No Treatment Group n = 10). Women without ‘Booking GDM’ (‘Decoys’
n = 58) and those in the No Treatment Group had a repeat OGTT at 24–28 weeks (with GDM treated if diagnosed).
Midwives and mothers were asked to complete surveys and attend focus groups before and after the study respectively
regarding their experiences and expectations of the study protocol.
Results: Sufficient women completed each step of the RCT. Gestation at OGTT was late at 18 ± 2 weeks with Treated and
No Treatment groups largely similar. At 24–28 weeks gestation, GDM was present in 8/9 (89%) in the No Treatment
group and 11/56 (20%) Decoys. NICU admission was highest in the Treated group (36% vs 0% p = 0.043), largely due to
small for gestational age, and Large for Gestational Age babies greatest in the No Treatment group (0% vs 33% p = 0.030).
Conclusion: An RCT deferring ‘Booking GDM’ treatment is feasible. Most women with untreated ‘Booking GDM’ in mid
2nd trimester had GDM at 24–28 weeks. Early treatment may have both benefits and harms. A full RCT is needed.
Trial registration: Australia New Zealand Clinical Trials Registry ACTRN12615000974505. Registered 17th May 2015; URL:
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369100&isReview=true Retrospectively Registered.
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Background
Gestational diabetes mellitus (GDM) increases the risk of
obstetric and neonatal complications, with future risks to
mother and baby [1–3]. Two randomised controlled trials
(RCTs) of GDM management from 24 to 28 weeks gesta-
tion, among women without pre-existing diabetes, showed
significant reductions in the risk of both macrosomia and
pre-eclampsia/Pregnancy Induced Hypertension [4, 5].
It has been recommended that women with possible
undiagnosed diabetes are identified early in pregnancy
and treated [6, 7]. However, during the screening
process, a significant proportion of women are identified
as below the biochemical criteria for ‘Diabetes in Preg-
nancy’, yet fulfilling criteria for GDM at 24–28 weeks
gestation. Fasting glucose can be higher at the beginning
of pregnancy [8], with one Chinese study reporting that
many women with ‘early GDM’ did not have GDM when
the oral glucose tolerance test (OGTT) was repeated at
24–28 weeks [8]. This has led to calls not to use the 24–
28 week GDM criteria earlier in pregnancy [9]. However,
this has left a void, with no recommendations on the
next management steps for women with lesser degrees
of hyperglycaemia early in pregnancy.
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The Treatment of BOoking Gestational diabetes Melli-
tus (ToBOGM) Study is a randomised controlled trial
(RCT) developed to test whether women with ‘hypergly-
caemia’ at booking (Booking GDM), should be treated to
avoid GDM complications, or whether earlier treatment
increases other pregnancy complications. We now report
on the findings of the ToBOGM pilot RCT investigating
recruitment, proportion with ‘GDM’ at booking, blinding
procedures, uptake of heel-prick glucose and outcome
measures to facilitate power calculations.
Methods
The primary aim of this pilot study was to test the
protocol for a larger scale RCT of either immediate or
deferred treatment for Booking GDM. Clinic midwives
at the Campbelltown Hospital Book-in clinic (i.e. first
antenatal clinic attendance) assessed the need of all
pregnant women for early testing for Diabetes in Preg-
nancy, based upon GDM Risk factors [10]. Women are
referred for a 75 g, 3 point, 2 h oral glucose tolerance
test (OGTT) as per local policy. Between July 20th 2015
and April 7th 2016, consecutive pregnant women at 4
to 19 + 6 weeks gestation, with a singleton pregnancy,
aged ≥18 years and referred for an OGTT were in-
vited to participate. Exclusions were inability to
understand English, or a presence of a major active
medical disorder. Consenting women completed ques-
tionnaires at baseline, 24–28 and 34–38 weeks and
attended a study OGTT appointment. Other data
were extracted from the clinical notes.
OGTT results were sent to one investigator (DS).
Women with Diabetes In Pregnancy (fasting ≥7.0 and/or
2 h ≥ 11.1 mmol/l) were referred immediately to the
clinic for treatment. Women below the 24–28 week
GDM [4] criteria (fasting ≥5.1 and/or 1 h ≥ 10.0 mmol/l
and/or 2 h ≥ 8.5 mmol/l), were advised that they did not
require referral to the clinic (‘decoys’). Such decoys
blinded the obstetric team as to whether women in-
volved in ToBOGM were controls or women without
‘hyperglycaemia’. Women fulfilling criteria for GDM
were randomised to either referral to the clinic (Treated)
or were advised (using identical letters to the ‘decoys’)
that they did not require referral to the clinic (No Treat-
ment). The participant, as well as midwifery, obstetric,
diabetes clinic, and research staff were kept blinded to
all numeric results and only knew if a woman had been
referred for GDM treatment. Randomisation to either
immediate or deferred treatment was undertaken
using an electronic randomiser (SPSS Version 22.0,
IBM, USA), stratified as either low risk (fasting 5.1–5.
2 mmol/l, 1 h 10–10.5 mmol/l and /or 2 h 8.5–8.
9 mmol/l) or high risk (based upon the IADPSG 2
fold excess risk of adverse outcomes at 24–28 weeks
gestation [6]: fasting 5.3–6.9 mmol/l, 1 h ≥ 10.6 mmol/l
and /or 2 h 9.0–11.0 mmol/l).
All women receiving treatment for GDM received
group education, were taught to self-monitor blood
glucose and saw a dietitian. Fasting and 2 h post-
prandial glucose targets were < 5.3 mmol/l and < 6.
8 mmol/l respectively [5]. Where glucose thresholds
were exceeded on more than two occasions with no
obvious cause, women were offered medication
(metformin or insulin treatment). Only women not
referred to clinic attended a 24–28 week OGTT,
and were referred for treatment if GDM was
diagnosed.
All women were asked for their baby to provide a
heel prick glucose 1–2 h after birth. Venous umbil-
ical cord blood was drawn into EDTA tubes for
assessing a range of metabolites and assessing the
adipo-insular axis. Glucose, triglyceride and 3-beta
hydroxy butyrate were measured in a single Inter-
national Organization for Standardization accredited
laboratory. Plasma insulin and C-peptide levels were
measured using a sandwich chemiluminescence im-
munoassay (Liaison XL, Diasorin, Saluggia, Italy).
Leptin and adiponectin measurements were deter-
mined using a radioimmunoassay kit (Merck Milli-
pore, Darmstadt Germany).
Qualitative assessment
Midwives at Campbelltown Hospital completed a survey
prior to the pilot study commencing. An additional one
hour focus group was conducted with a group of midwives
(n = 6) at the conclusion of the pilot study, to examine their
experience of taking part in the RCT. A survey was also
completed by mothers who were booked into the clinic at
Campbelltown Hospital for antenatal care. A group of
mothers (n = 4) also took part in a focus group at the con-
clusion of the pilot study. The midwife and the mothers’
surveys both contained demographic questions, closed
ended questions about knowledge of GDM and open ended
questions about expectations and experiences of the pilot
study protocol. In the focus groups, the midwives and
mothers were asked about their expectations and experi-
ences of GDM and the study protocol. The focus groups
were audio recorded and transcribed verbatim. Focus
group transcripts and open ended interviews were
analysed using thematic analysis [11]. This involved
reading through the qualitative data, developing a
coding frame based on commonality of responses
across participants, leading to identification of themes
that captured expectations and experiences of GDM
and involvement in the study. The themes included
acceptability, unacceptability, concerns, absence of
concerns, and importance of mothers consent.
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Statistics
As a pilot, limited by funding, a target was set to randomise
20 women with GDM at booking, with an expectation,
based upon a prior study [12], that 100 women would need
to be consented to meet this target. Mean and standard de-
viations are reported for continuous variables, and number
and percentages are reported for categorical variables. Geo-
metric mean is used for non-normally distributed biochem-
ical measurements [13]. All tests are 2 tailed. Analyses were
undertaken using SPSS Version 22.0 (IBM, USA) with pro-
portions compared using Chi squared test and continuous
variables compared using Analysis of Variance. The study
was approved by the South Western Sydney Local Health
District Ethics committee (reference 15/LPOOL/14).
Results
Figure 1 includes the numbers invited (607), consented
(100), and randomised (22). One woman randomised to
No Treatment decided to withdraw from the trial and
was referred to the GDM clinic and treated. Of the 128
eligible women, 100 (78.1%) consented and 79 (61.7%)
entered the study. The randomisation process was ad-
hered to, 88% of babies had the heel prick test and other
outcomes were available for 96% of women/babies.
Table 1 compares the Treated and No Treatment
groups, and ‘any booking GDM’ with the decoys. Com-
pared with decoys, women with booking GDM had
higher baseline BMI, serum insulin, leptin and 3 beta
hydroxyl butyrate concentrations and lower adiponectin
Fig. 1 CONSORT diagram: Study uptake at different stages in the ToBOGM Feasibility Randomised Controlled Trial
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Decoys Sig GDM vs Decoyb Sig referred to
clinic vs not referred
to clinic at Bookingc
N Baseline/ Outcomes 11/11 10/9 a 58/56
Age 29(5) 30(7) 28(5) 0.181 0.746
Non Europid 4 (36.4%) 5(50%) 30(51.7%) 0.486 0.528
University degree 2 (18.2%) 1(10%) 11(19%) 0.630 0.593
Family History of Diabetes 4 (36.4%) 3(30%) 25(43.1%) 0.435 0.757
Smoker 0 (0%) 2(20%) 9(15.5%) 0.497 0.119
Gestation on entry (weeks) 17.0(2.1) 15.7(3.1) 15.3(2.5) 0.114 0.277
Gestation at OGTT (weeks) 18.5(1.2) 17.5(1.8) 17.5(2.0) 0.307 0.173
Systolic BP(mmHg) 111(11) 101(8) 106(12) 0.857 0.029
Diastolic BP (mmHg) 64(7) 63(9) 64(9) 0.837 0.693
Height (cm) 164(6) 164(8) 163(8) 0.790 0.948
Weight (kg) 87.2(23.7) 89.9(26.4) 77.8(20.9) 0.057 0.807
BMI (kg/m2) 32.3 (7.8) 33(7.0) 28.9(6.6) 0.034 0.824
Fasting glucose (mmol/L) 5.1(0.4) 5.2(0.3) 4.6(0.3) < 0.001 0.464
1 h glucose (mmol/L) 8.0(1.7) (n = 10) 8.4(1.6) 6.7(1.4) < 0.001 0.602
2 h glucose (mmol/L) 7.0(1.9) (n = 10) 6.8(1.7) 5.6(1.2) 0.001 0.790
Maternal Fasting Insulin (pmol/L) 118.2 122.4 (n = 9) 59.8 (n = 53) < 0.001 0.910
Maternal Fasting Cpeptide (pmol/L) 426.5 686.9 (n = 9) 412.1 (n = 53) 0.190 0.379
Maternal Fasting Adiponectin(μg/mL) 7.2(2.4) 9.5(2.9) (n = 9) 12.1(7.5) (n = 53) 0.028 0.071
Maternal Fasting Triglyceride(mmol/L) 1.8(0.6) 1.9(0.5) (n = 9) 1.7(0.7) (n = 51) 0.370 0.748
Maternal Fasting Leptin(ng/mL) 57.6(30.0) 69.4(25.0) (n = 9) 46.1(25.4) (n = 53) 0.016 0.360
Maternal Fasting 3 BHB(μmol/L) 96.9 98.3 (n = 9) 64.0 (n = 53) 0.002 0.950
GDM at 24–28/40 – 8/9 a(89%) 11/56(19.6%)
Insulin and/or metformin 4/11 (36%) 4/10(40%) 3/11(27.3%) 0.443 0.864
Gestation at birth (weeks) 38.7(1.4) 39.2(0.6) 38.5(2.2) 0.440 0.326
Gestational weight gain 5.3(3.7) 8.1(2.5) 10.4(5.3) 0.001 0.074
Pre-eclampsia/pregnancy induced hypertension 3(27%) 0(0%) 6(10.7%) 0.664 0.089
Male baby 6(55%) 6(67%) 22(39%) 0.160 0.582
Induction of labour 7(64%) 3(33%) 9(16%) 0.001 0.178
Emergency CS Elective CS 4(36%) 1(9%) 1(11%) 2(22%) 7(13%) 14(25%) 0.236 0.313 0.194 0.413










Neonatal Glucose %≤ 2.2 mmol/l 1/9 (11%) 1/8(13%) 6/46(13%) 0.834 0.929
Weight of baby (g) 3055(758) 3552(743) 3339(682) 0.873 0.159
Average Centile 46(39) 57(35) 56(34) 0.801 0.531
<10th Centile 3(27%) 0(0%) 5(8.9%) 0.493 0.089
>90th Centile 0 3(33%) 14(25%) 0.583 0.030
aOne woman withdrew and was referred for treatment: she consented to data being collected and is included in the GDM vs Decoy comparison but not the
Referred vs Not Referred comparison
bSig GDM vs Decoy = significance of difference between all women with and without GDM at booking
cSig referred to clinic vs not referred to clinic at Booking = significance of difference between women with GDM at booking who were or were not referred
to clinic
Mean APGAR 1 min and 5 min =9(1); Not referred: one shoulder dystocia
Statistically significant comparisons shown in italics
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levels. At baseline, 4/21 (19%) with booking GDM, were
diagnosed at the low and 17/21 (81%) at the higher
glycaemic stratum; 17/21 (81%) had an elevated fasting
glucose level with or without a higher post load glucose.
Treated women had a higher systolic blood pressure
than No Treatment women at baseline. Among the
remaining women randomised to No Treatment, 8/9
(89%) had GDM on the 24–28 week OGTT while 11/56
(19.6%) had developed GDM in the decoy group. There
were no differences between the Treated and No Treat-
ment group for gestational age at delivery. Babies of
women in the No Treatment group were more likely to
have a large for gestational age (LGA) baby (p = 0.03),
but babies of women in the Treated group were more
likely to be admitted to NICU (p = 0.043: three small
gestational age (SGA), one of whom was < 37 weeks).
The only stillbirth was in the No Treatment group with
placental abruption (not considered to be due to delayed
treatment). Compared with women with booking GDM,
decoys had more gestational weight gain (p = 0.001) and
were less likely to be induced (p = 0.001).
The characteristics of midwives and women participat-
ing in the survey and focus groups are shown in
Additional file 1: Table S1 and Additional file 2: Table S2.
Of the women, one was a participant in the pilot study,
one was currently pregnant but did not have GDM, one
had recently had a baby and did not have GDM, and
one had GDM in a previous pregnancy. All were familiar
with the OGTT testing in pregnancy. Tables 2 and 3
describe the qualitative responses of midwives and
Table 2 Midwives’ perspectives on key study procedures – qualitative responses
What are your thoughts on the study specifically approaching
women in the booking clinic to participate, who have been
identified as at risk for GDM?
Acceptable
• Recruitment strategy is ‘good’, ‘good idea’ or ‘fantastic idea’ (S: 7)
No concerns
• No concerns regarding the ethics of approaching this group (F: 3)
• Neutral or no concerns recruitment (S: 6)
Concerns
• Consent is an important issue, women should be aware of what their participation
would involve e.g. blinding of results, potential withholding of treatment (F: 3, S: 1)
• Do not agree with the deliberate recruitment of an at risk population (S: 1)
What do you think about delaying treatment, if needed, to 24
to 28 weeks?
Acceptable
• Treatment timing is acceptable/appropriate (S: 8)
• Acceptable, as standard procedures used to be based on 28 weeks to detect GDM
(S: 1, F: 1)
• More information/research needed on the outcomes of delayed treatment (S: 2)
Concerns
• Concern about the legal and ethical issues of providing adequate ‘duty of care’ to
patients whose results were withheld due to research participation (F: 2)
• Concern that researchers could make a mistake in identifying at-risk patients and
delaying treatment (S: 2)
• No issue unless GDM is detected earlier, then treatment should not be delayed (S: 3)
Not acceptable
• Not acceptable, testing and treatment should be made earlier to prevent risk to the
mother and foetus e.g. could be too late to treat, to educate mother, prevent
complications (S: 4)
• Detection and treatment should occur earlier only if risk factors are present (S: 2)
• Treatment delay could prevent mothers from experiencing unnecessary anxiety
about their pregnancy (F:3)
• Unsure (S: 1)
How do you feel about the heel prick test for glucose at one
hour old?
Acceptable
• Midwives were not concerned as it was not part of their workload (F: 2)
• Baby’s best interests and health the main priority (S: 1)
• Test is needed and therefore there should be no concerns (S: 5)
• Not necessary as already part of standard care (S: 4)
• Test okay if managed professionally (S: 1)
• Test should occur on the basis it will assist in health research (S: 1)
Importance of mothers’ consent
• Mothers’ consent/refusal must be respected (S: 7)
• Mothers’ should be educated and given opportunity to consent, prior to birth (S: 4)
• Issues with consent can only be dealt with if there is ‘medical indication’ that test
must be done, and a subsequent “refusal of treatment” is put in clinical notes (S: 1)
• Concern that test may not be conducted due to mothers’ viewing it as unnecessary
despite previously consenting (F: 2)
Concerns
• Test may not be undertaken due to staff being overworked/too busy (S: 1)
• Unnecessary for babies who do not have a diabetic mother (F: 1)
S Survey responses, F Focus group responses
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antenatal women respectively from the open ended sur-
vey questions and focus groups. Overall, the midwives’
and the mothers responded positively to the study pro-
cedures. Respondents gave feedback on the importance
of informed consent throughout all stages of the study.
Most women reported preferring face-to-face initial con-
tact. There were some concerns around the ethics of
delaying treatment. The heelprick glucose was widely
accepted. In the focus group, the midwives talked about
the need to have a researcher dedicated to the study in
the clinic, so that the study did not impact on their
workload.
Discussion
We have shown that our study protocol was feasible, re-
quiring few changes. Randomisation and each step of
the protocol were implemented with no significant prob-
lems. Both the mothers interviewed and the midwives
were generally positive about the procedures, although
there was some concern over the delay in treatment for
women allocated to the No Treatment condition. In
spite of this, most eligible women consented to the RCT
and were able to enter the study.
Our overall capture rate for the heel prick was over
80%, higher than the 71.25% in HAPO [14]. Those not
Table 3 Mothers’ perspectives on key study procedures – qualitative responses
What are your thoughts on the study specifically approaching
women in the booking clinic to participate, who have been
identified as at risk for GDM?
• Women described the recruitment process positively and had no objection
to being approached (S: 4)
• Clinic recruitment was considered a good research strategy (S: 2)
• Women described that the recruitment process was a positive as it raised
awareness of GDM in regards to education on diet, complications and
prevention (S: 2)
• Women liked that recruitment was conducted by a person, as it aided the
establishment of rapport and understanding of the study (F:2, S: 1)
• Flyers or pre-clinic booking would help give mothers time before being
approached in clinic to make a decision (S: 2)
• Mothers preferred being approached face-to-face as opposed to via a flyer
or email (F: 2)
• Face-to-face increases chances of participation (F: 1)
What do you think about delaying treatment, if needed, to
24 to 28 weeks?
Good or okay to delay
• Participants described delayed treatment as a good idea (S: 6, F:1)
• Participant indicated that if the early GDM test was not necessary it could
save Medicare resources (S: 1)
• Mothers preferred to be only tested at 28 weeks, as it is standard practice in
many places and in the past (F: 1)
• Mother approved of the delay, as she thought her own early testing and
treatment was invasive and unnecessary (F: 1)




• Not sure (S: 5)
Should not delay
• GDM should not be delayed if it can be treated early (S: 1. F: 1)
• Mother would still want to check at booking (S: 1)
• Delaying treatment would be detrimental to mother and child as there is
no need
to change the current approach to treatment at booking (S: 1)
• Participant expressed that if detected some treatment should occur, even if
that is
just a modified diet (S: 1, F: 1)
• Treatment should not be delayed (S: 1, F: 1)
How do you feel about the heel prick test for glucose at one
hour old?
Good or okay
• Good, no problems with test (S: 10, F: 3)
• Mothers describe having no objection based on the notion that test will
aid in
checking health of baby/identification of diabetes (S: 2, F:1)
• Only if necessary (S: 7)
• No objection as babies have lots of tests when born anyway (S: 2, F:1)
• Mothers described that babies forget pain quickly (F: 2)
Not approve or ambivalent
• Not comfortable with test (S: 3)
• Mother described being uncomfortable if the test disturbed the baby (S: 1)
• Opposed ‘I refuse to see that’ (F:1)
• This test should have second consent obtained (F: 2)
• Mothers suggested that less blood be collected (F:1)
S Survey responses, F Focus group responses
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captured included three premature births that occurred
at a neighbouring hospital, a stillbirth, and the remain-
der not collected due to participants being discharged
early and lost to follow-up. We hope to improve the
heel-prick capture rate through providing more informa-
tion to midwives and by providing participants with leaf-
lets/bags with the study logo so that midwives are aware
of their involvement in the study and the importance of
capturing the heel-prick.
Although small, our study is the first to show that
early GDM treatment could be associated with a play off
between a reduced LGA rate but an increased NICU
admission rate (largely associated with SGA for those
treated from booking). SGA/fetal undernutrition can be
a consequence of overtreatment [15], or insufficient
gestational weight gain [16], with putative long term
consequences [17]. Hypertension and smoking (and po-
tentially metformin treatment [18]) can also contribute
to reduced fetal growth and in the main trial, it will be
important to assess any interaction between these char-
acteristics, fetal gender and outcomes from early GDM
treatment. Our study reminds us that we do not know
the optimal glycaemic targets early in pregnancy and
that we should be cautious. Our study is also the first to
challenge the finding that 33–66% of women early in
pregnancy might not have GDM on repeat fasting glu-
cose testing [8]. As 89% of untreated women in our
study had GDM at both 18 weeks and 24–28 weeks ges-
tation, there is a case for using the 24–28 week criteria
from the middle of the second trimester.
Our study has the strength of obstetrician blinding
and the use of decoys, to avoid confounding of the
NICU admission and LSCS rates. The use of quantitative
and qualitative measures is also a strength. The study
only tests the use of the IADPSG/WHO criteria [6, 7]
and not other criteria for GDM. Weaknesses include the
higher baseline systolic blood pressure and the small
sample size. The latter prevents the identification of the
impact of any specific management issues such as the
use of metformin or treatment compliance. The late
clinic booking of women was a major impediment to re-
cruitment and we have tested the benefits/harms with a
mid-second, not a first trimester GDM diagnosis. Most
(48%) of the exclusions were due to this late booking,
which was due to local clinic processes (now rectified).
For the main study, we have negotiated with the ante-
natal clinic to expedite the booking of women with risk
factors for GDM, to avoid delays and hopefully recruit
before 12–14 weeks gestation. Such earlier recruitment
is more likely to directly answer the question about the
benefits/risks of treatment in the first trimester raised by
both Zhu et al. [8] and Sweeting et al. [19]. The latter
showed that the group with the poorest pregnancy
outcome were diagnosed before 12 weeks. Women
diagnosed with GDM between 13 and 23 weeks had out-
comes more similar to those diagnosed > 24 weeks. The
study would have recruited the target number of women
quicker if an early OGTT had been requested univer-
sally. However, the study followed the national guideline
to use risk factor screening to assess who should
proceed to an early OGTT.
Conclusion
In conclusion, we have completed the first RCT of
whether GDM, defined by 24–28 week criteria, should
be treated at booking. Our surveys and interviews of
mothers and midwives, along with the successful com-
pletion of the study highlights its feasibility. Although a
small study, the findings suggest that there may be a play
off between reducing macrosomia and increasing fetal
undernutrition, a finding warranting a larger RCT. A full
trial is urgently required.
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